Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.
Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
Harrow Announces Participation in Upcoming Investor Conferences
Harrow Announces Third Quarter 2024 Financial Results
Harrow Launches Access and Affordability Program with Price Reductions for Branded Products